▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1896 by analyst upside · 2026-09-29
AMLX
Amylyx Pharmaceuticals, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+41.9%
implied upside to consensus target
Current Price $29.85
Consensus Target $42.36
Bull Target $57.0
Bear Target $20.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
10
Hold
1
Sell
0
52-Week Low $10.83
52-Week High $41.14
YTD Return +161.4%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.43
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $10.83
52-Week High $41.14
Current Price $29.85
Bear Target $20.0
Bull Target $57.0
● Now $29.85 ● Target $42.36
TRADING DATA
Avg Volume 2.4M
YTD Return +161.4%
Analyst Count 11
Consensus Buy
Upside to Target +41.9%
Last Updated 2026-09-29

ANALYST SUMMARY

Amylyx Pharmaceuticals, Inc. (AMLX) is currently trading at $29.85 with a Wall Street consensus price target of $42.36, implying potential upside of 41.9% over the next 12 months. 11 analysts currently cover AMLX, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $57.0, while the most cautious has a target of $20.0.

AMLX operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 161.4% year-to-date and is currently trading near the upper end of its 52-week range of $10.83 – $41.14.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AMLX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-08-27 62% win rate (8 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-08-19 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-19 62% win rate (8 calls)
Baird - Reiterated
Outperform → Outperform 2026-08-19 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-18 31% win rate (48 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-08-17 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-03 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-07-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
5/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →